Patents by Inventor Artur Schmidtchen
Artur Schmidtchen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230218727Abstract: The present invention relates to TCP peptides for use in methods of treatment of S protein viruses. Notably, said TCP peptides are useful for treatment of inflammation associated with infection by S protein virus. The invention also provides methods for predicting the severity of infection by S protein virus.Type: ApplicationFiled: June 25, 2021Publication date: July 13, 2023Inventors: Artur Schmidtchen, Ganna Petruk, Manoj Puthia
-
Publication number: 20230127258Abstract: The present invention relates to compositions comprising: a) a thrombin derived peptide and, b) a non-ionic polymer capable of forming a hydrogel and c) an aqueous solution. The invention also provides compositions comprising: a) a thrombin derived peptide and, b) EDTA and c) an aqueous buffer. The invention also provides compositions comprising: a) a thrombin derived peptide in high concentration. A product comprising the compositions, as well as the compositions or the products for use in a method of treatment are also disclosed.Type: ApplicationFiled: November 18, 2020Publication date: April 27, 2023Inventors: Artur Schmidtchen, Manoj Puthia, Ganna Petruk
-
Patent number: 9169315Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOS: 1 to 3, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: GrantFiled: September 21, 2010Date of Patent: October 27, 2015Assignee: XIMMUNE ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Björn Ulrik Walse
-
Patent number: 8735353Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 7, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: GrantFiled: September 22, 2010Date of Patent: May 27, 2014Assignee: XMedic ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Bjorn Ulrik Walse
-
Patent number: 8551954Abstract: An antimicrobial peptide with heparin binding activity is described. It can be derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acids residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K,R, and H. Also described are pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.Type: GrantFiled: October 23, 2007Date of Patent: October 8, 2013Assignee: Pergamum ABInventors: Artur Schmidtchen, Martin Malmsten
-
Publication number: 20130052258Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 7, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: ApplicationFiled: September 22, 2010Publication date: February 28, 2013Applicant: XMEDIC ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Bjorn Ulrik Walse
-
Publication number: 20120189673Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOs: 1 to 11, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof which exhibit an anti-inflammatory and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: ApplicationFiled: September 22, 2010Publication date: July 26, 2012Inventors: Martina Kalle, Nils Martin Malmsten, Praveen Papareddy, Victoria Rydengard, Artur Schmidtchen, Björn Ulrik Walse
-
Patent number: 8227406Abstract: The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.Type: GrantFiled: May 15, 2007Date of Patent: July 24, 2012Assignee: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten
-
Publication number: 20120177715Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOS: 1 to 3, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: ApplicationFiled: September 21, 2010Publication date: July 12, 2012Applicant: XIMMUNE ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Björn Ulrik Walse
-
Patent number: 8076286Abstract: The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.Type: GrantFiled: February 12, 2007Date of Patent: December 13, 2011Assignee: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten, Björn Walse
-
Publication number: 20100159006Abstract: The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activityType: ApplicationFiled: May 15, 2007Publication date: June 24, 2010Applicant: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten
-
Publication number: 20090312265Abstract: The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.Type: ApplicationFiled: February 12, 2007Publication date: December 17, 2009Applicant: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten, Björn Walse
-
Publication number: 20090143299Abstract: The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is not R, X8 is I or L, X10 is not H and wherein said molecule have a length of from about 10 to about 100 amino acid residues or an analogue thereof. The invention also relates to compositions comprising said molecule and use of the molecule and/or composition of the invention to combat microorganisms, such as bacteria, viruses, fungi, including yeast, and parasites.Type: ApplicationFiled: February 10, 2007Publication date: June 4, 2009Inventors: Artur Schmidtchen, Martin Malmsten, Bjorn Walse
-
Publication number: 20090074864Abstract: The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.Type: ApplicationFiled: October 23, 2007Publication date: March 19, 2009Applicant: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten
-
Publication number: 20080069849Abstract: The invention relates to the use of peptides, wherein at least one amino acid residue has been substituted to improve the efficacy of the antimicrobial peptide for the manufacturing of an antimicrobial composition. The composition can be used as a pharmaceutical composition to combat microorganisms, such as bacteria, virus, fungus, parasites as well as yeast.Type: ApplicationFiled: November 17, 2005Publication date: March 20, 2008Applicant: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten, Bjorn Walse
-
Patent number: 7335355Abstract: A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the testType: GrantFiled: July 17, 2001Date of Patent: February 26, 2008Assignee: Hansa Medical ABInventors: Lars Bjorck, Inga-Maria Frick, Artur Schmidtchen
-
Publication number: 20070185019Abstract: The invention relates to an antimicrobial peptide with heparin binding activity, being derived from endogenous mammalian proteins being substantially free from antimicrobial activity selected from the group consisting of laminin isoforms, complement factor C3, histidin rich glycoprotein and kininogen and having from 10 to 36 amino acid residues, wherein the antimicrobial peptide consists of at least four amino acid residues selected from the group consisting of K, R and H. The invention also relates to pharmaceutical compositions comprising said antimicrobial peptide and use of the antimicrobial peptide and/or antimicrobial/pharmaceutical composition.Type: ApplicationFiled: May 19, 2004Publication date: August 9, 2007Applicant: DERMAGEN ABInventors: Artur Schmidtchen, Martin Malmsten
-
Publication number: 20040028672Abstract: A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the testType: ApplicationFiled: May 28, 2003Publication date: February 12, 2004Inventors: Lars Bjorck, Inga-Maria Frick, Artur Schmidtchen